Have a feature idea you'd love to see implemented?
Let us know!
CDTX Cidara Therapeutics Inc
Price (delayed)
$10.85
Market cap
$76.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25.27
Enterprise value
-$83.7M
Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its
Highlights
Cidara Therapeutics's quick ratio has soared by 137% YoY
CDTX's debt is down by 7% QoQ and by 5% YoY
The gross profit has plunged by 56% YoY and by 12% from the previous quarter
The company's revenue has shrunk by 53% YoY and by 11% QoQ
Key stats
What are the main financial stats of CDTX
Market
Valuations
Earnings
Shares outstanding
7.04M
Market cap
$76.36M
Enterprise value
-$83.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
1.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.14
Revenue
$39.07M
EBIT
-$115.02M
EBITDA
-$113.89M
Free cash flow
-$125.11M
Per share
Balance sheet
Liquidity
EPS
-$25.27
Free cash flow per share
-$27.41
Book value per share
$28.7
Revenue per share
$8.56
TBVPS
$37.99
Total assets
$173.36M
Total liabilities
$42.42M
Debt
$4.3M
Equity
$130.94M
Working capital
$128.95M
Debt to equity
0.03
Current ratio
4.25
Quick ratio
4.21
Net debt/EBITDA
1.41
Margins
Efficiency
Dividend
EBITDA margin
-291.5%
Gross margin
92.1%
Net margin
-295.2%
Operating margin
-310.5%
Return on assets
-129.4%
Return on equity
-408.3%
Return on invested capital
N/A
Return on capital employed
-86%
Return on sales
-294.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDTX stock price
How has the Cidara Therapeutics stock price performed over time
Intraday
1.31%
1 week
2.84%
1 month
-7.26%
1 year
-42.29%
YTD
-31.68%
QTD
0.93%
Financial performance
How have Cidara Therapeutics's revenue and profit performed over time
Revenue
$39.07M
Gross profit
$35.98M
Operating income
-$121.3M
Net income
-$115.32M
Gross margin
92.1%
Net margin
-295.2%
The gross profit has plunged by 56% YoY and by 12% from the previous quarter
The company's revenue has shrunk by 53% YoY and by 11% QoQ
Cidara Therapeutics's gross margin has decreased by 8% YoY
Growth
What is Cidara Therapeutics's growth rate over time
Valuation
What is Cidara Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
1.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.14
CDTX's price to sales (P/S) is 62% lower than its 5-year quarterly average of 3.3 and 17% lower than its last 4 quarters average of 1.5
The company's revenue has shrunk by 53% YoY and by 11% QoQ
Efficiency
How efficient is Cidara Therapeutics business performance
Cidara Therapeutics's return on equity has shrunk by 128% YoY
Cidara Therapeutics's return on assets has shrunk by 115% QoQ
Dividends
What is CDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDTX.
Financial health
How did Cidara Therapeutics financials performed over time
The total assets has soared by 155% YoY
Cidara Therapeutics's quick ratio has soared by 137% YoY
CDTX's debt is 97% lower than its equity
Cidara Therapeutics's debt to equity has soared by 112% from the previous quarter but it has plunged by 90% YoY
CDTX's debt is down by 7% QoQ and by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.